Sources said that the government is negotiating on price with Serum Institute and that its competitor Bharat Biotech may price its candidate Covaxin lower. Of the 100 million doses almost ready with the Pune-based Serum Institute, some of that would be used to meet its international commitments. The international shipments are likely to start moving around March.
Adar Poonawalla, CEO of Serum Institute, has said the price of Covishield would be Rs 200 per dose for the first 100 million doses supplied to the government. By March, Hyderabad-based Bharat Biotech too may have efficacy data from its phase 3 trials. It completed recruitment for the trials on Thursday. Bharat Biotech has 10 million doses of Covaxin ready and can have another 10 million in the next few weeks. It can, therefore, supply 20 million doses to the government at the moment for its vaccine which got restricted use approval in clinical trial mode.